Anaesthesiology

Smokers and those exposed to passive smoke require more anesthetic and painkiller during operations

 

Brussels, Belgium (May 29, 2015) – Research published at this year’s Euroanaesthesia meeting in Berlin (30 May-2 June) shows that both smokers and those exposed to passive smoke require more anaesthetic and painkillers to reach the same level of anaesthesia as non-smokers. The study is by Dr Erdogan Ozturk, Department of Anaesthesiology and Intensive Care, Bezmialem Vakif University, Istanbul, Turkey, and colleagues.


Tobacco smoke consists of more than 4,000 particles with toxic and carcinogenic (cancer causing) properties, in both gas and particulate form. A limited number of studies exist indicating that smoking increases anaesthetic requirements; however the anaesthetic requirements for people exposed to environmental tobacco smoke (passive smokers) has not been studied at all. In this new study, the authors investigated whether there is a difference among smokers (S), passive smokers (PS), and non-smokers (NS) in terms of intraoperative anaesthetic and painkiller consumption.

 

A total of 90 women undergoing total abdominal hysterectomy were enrolled in the study. The patients were divided into three groups (30 patients each) based on smoke exposure, confirmed by measurement of serum cotinine (a metabolite of nicotine and marker of tobacco smoke exposure). Group S consisted of smokers, Group PS consisted of passive smokers, and Group NS, consisted of women with no history of smoking and also no environmental smoke exposure.

 

Standard total intravenous anaesthesia was performed on all patients. Bispectral index value (BIS) value (a guide to the patient’s level of consciousness) was maintained between 40-60. After the operation, the total amount of the anaesthetic propofol and the painkiller remifentanil used was recorded.

 

The amount of propofol used for induction of anaesthesia was, for Group S, PS and NS, 102.76 mg, 84.53 mg, 63.17 mg respectively. In Group S the amount was 38% higher than in Group NS and 17% higher than in Group PS, and in Group PS the amount used was higher 18% than in Group NS.

 

Total propofol usage throughout the whole anaesthesia was also different between groups: for Group S, PS, and NS the amounts used were 179.38 mg, 150.50 mg, and 119.37 mg respectively. In Group S the amount used was 33% higher than in Group NS and 16% higher than in Group PS, and in Group PS 20% higher than in Group NS.

 

The total amount of the painkiller remifentanil used was, for Group S, PS, and NS: 1315 µg, 1241 µg, and 1010 µg respectively. Group S had 23% higher usage than Group NS and 6% more compared to Group PS; and in Group PS usage was higher 18% than in Group NS.

 

The authors conclude: "The amounts of anaesthetic and painkiller required to ensure equal anaesthetic depth in similar surgeries was higher in active smokers and passive smokers compared to non-smokers."

 

They suggest that nicotine could affect the metabolism of anaesthetic drugs in the liver, or may desensitise of the some nociceptors (nerve cells) that sense pain.

 


ESA (European Society of Anaesthesiology), 29.05.2015 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…